What is the PI-RADS score on prostate MRI and how does it influence your treatment? Complete guide for patients

Have you received a prostate magnetic resonance imaging (MRI) result and seen “PI-RADS 3” or “PI-RADS 4” written on it, but don’t understand what it means? It’s perfectly normal to feel overwhelmed. This guide breaks down the PI-RADS system into simple terms, explains what each score tells you about your risk of prostate cancer, and, more importantly, how this classification influences biopsy and treatment decisions.

1. What is the PI-RADS system?

When a radiologist analyzes images from multiparametric prostate MRI (mpMRI), they need a “standardized language” to communicate how suspicious an area is. This is where PI-RADS (Prostate Imaging Reporting and Data System), a reporting system developed by the American College of Radiology, comes in.

In short, PI-RADS is a scale from 1 to 5 that expresses the probability that a lesion visible on MRI represents clinically significant prostate cancer (i.e. a form that has the potential to grow and spread, as opposed to an indolent form, which evolves very slowly).

It’s important to remember: PI-RADS is not a diagnosis of cancer. It is a risk estimate, a “traffic light” that guides next steps. Only a biopsy can confirm with certainty the presence of cancer cells.

Keywords: what is PI-RADS, prostate MRI, PI-RADS score explained.

2. What does each PI-RADS score (from 1 to 5) mean?

Each number on the scale corresponds to a different level of suspicion. Here’s how it’s interpreted, in easy-to-understand language:

PI-RADS 1 – Very low: It is very unlikely that there is a clinically significant cancer. The tissue appears normal on MRI.
PI-RADS 2 – Low: Unlikely to be an aggressive cancer. The changes seen are most often benign.
PI-RADS 3 – Intermediate (equivocal): The presence of significant cancer is “uncertain”. This is the “gray” score, the most difficult to interpret, where the decision to biopsy or not depends on additional factors (see below).
PI-RADS 4 – High: Clinically significant cancer is likely. Targeted biopsy is usually recommended.
PI-RADS 5 – Very high: The lesion is very likely to be a clinically significant cancer, especially if it is large. Targeted biopsy is strongly recommended.

The higher the score, the greater the likelihood of discovering an aggressive form of cancer on biopsy.

Keywords: PI-RADS 3 means, PI-RADS 4 cancer risk, PI-RADS scale 1-5.

3. Why is MRI done BEFORE biopsy? The revolution in urology

In the past, any patient with an elevated PSA (prostate-specific antigen) was sent directly to a “blind” biopsy, which collected random samples from the prostate. Today, international guidelines have radically changed this approach.

The NCCN (National Comprehensive Cancer Network) guideline , one of the most respected standards in oncology, now recommends that multiparametric MRI precede biopsy (category 1 recommendation, highest level of evidence).

Why is this so important to you? Because MRI, through the PI-RADS score, allows the doctor to:

Avoid unnecessary biopsies. Studies show that using MRI before biopsy can reduce the number of unnecessary biopsies by 30% to 50%.
To precisely target the suspicious area. Instead of random sampling, the biopsy needle is guided directly to the lesion marked by the radiologist.
To avoid discovering indolent cancers that would never have caused problems, thus reducing overtreatment.

A concrete example comes from the PRECISION clinical trial : in the group that used MRI before biopsy, 28% of patients were able to avoid biopsy completely based on a normal MRI (PI-RADS below 3). In addition, more significant cancers and fewer low-risk forms were detected.

Keywords: MRI before prostate biopsy, targeted biopsy, NCCN prostate guideline.

4. PI-RADS implications in treatment decision: what comes after each score?

This is where the most important thing for the patient is. The PI-RADS score, always correlated with the PSA value and PSA density, guides the therapeutic steps.

PI-RADS 1 or 2 (Negative MRI)

The risk is usually low and biopsy can be avoided, especially if the PSA density is low. However, be careful: a negative MRI does not completely rule out cancer . The NCCN guideline states that if the PSA continues to rise persistently, biopsy should be considered even with a normal MRI. The doctor will decide to monitor with PSA and examination every 6–12 months.

PI-RADS 3 (uncertain area)

This is where the “additional artillery” comes into play: PSA density, risk calculators, and biomarkers (such as PHI, 4Kscore, SelectMDx, IsoPSA). These markers help decide whether a biopsy is truly necessary or can be safely postponed.

PI-RADS 4 or 5 (high suspicion)

MRI/ultrasound fusion-guided biopsy is recommended . The NCCN guideline emphasizes that the best strategy is a combined approach: targeted biopsy (on the lesion) plus systematic biopsy, as some aggressive cancers are only discovered by the systematic method.

What happens if the biopsy confirms cancer? This is where PI-RADS comes in again. A high MRI score often correlates with:

Tumor staging (local extension, if the tumor has exceeded the prostate capsule);
The risk of aggressiveness, which combines with the Grade Group obtained at biopsy.

Based on this data, the doctor determines the risk group (low, intermediate, high) and, together with you, chooses between active surveillance , radical prostatectomy (surgery), radiotherapy or androgen deprivation therapy (ADT) .

Keywords: prostate cancer treatment, active surveillance, MRI fusion biopsy.

5. PI-RADS Limitations: Why Experience and Data Correlation Matter

Although PI-RADS is a great tool, it also has limitations that an informed patient should be aware of:

It depends on the experience of the radiologist. The NCCN guideline draws attention to the high variability between interpretations of different radiologists and emphasizes the need for high-quality equipment and radiological expertise.
False-negative results do occur. The negative predictive value of mpMRI for significant cancer is approximately 86%–98%, meaning that a small percentage of cancers may be missed.
It does not work in isolation. PI-RADS should always be correlated with PSA, PSA density, age, family history, and possible biomarkers.

Precisely because of this complexity, a “second opinion” and integrated analysis of all documents become essential.

📊 Table: Quick guide to PI-RADS score – what it means and what comes next

PI-RADS score	🚦 Meaning (level of suspicion)	What does it say about risk?	➡️ What comes next, usually
PI-RADS 1	🟢 Very low	Very unlikely significant cancer. Normal tissue on MRI.	PSA monitoring; biopsy can be avoided.
PI-RADS 2	🟢 Low	Unlikely to be an aggressive cancer. Changes most often benign.	Monitoring; biopsy correlates with PSA density.
PI-RADS 3	🟡 Intermediate (uncertain)	The presence of significant cancer is “uncertain” – the “gray” area.	PSA density, biomarkers (PHI, 4Kscore, SelectMDx) are added to decide on biopsy.
PI-RADS 4	🟠 High	Probably a clinically significant cancer.	MRI/ultrasound guided targeted biopsy recommended.
PI-RADS 5	🔴 Very high	Very likely a significant cancer, especially if the lesion is large.	Targeted biopsy strongly recommended.

🔑 To remember (caption for the patient):

Symbol / Term	Explanation in your language
🟢 Green (1–2)	“Relative quiet” – the risk of aggressive cancer is low.
🟡 Yellow (3)	“Decision zone” – additional testing is needed.
🟠 🔴 Red (4–5)	“Signal for action” – biopsy is recommended.
Targeted biopsy	Precise harvesting from the area marked on the MRI (not at random).
PSA / PSA density	Blood tests that combine with the PI-RADS score for a complete picture.

⚠️ Important note: A low score (PI-RADS 1–2 / MRI negative) does not completely rule out cancer. If PSA is persistently elevated, your doctor may recommend a biopsy even with a normal MRI.

PI-RADS Algorithm – Patient Guide (table format)

📋 STEP 1 – Initial assessment

Your situation	What’s next?
PSA > 3 ng/mL and/or suspicious rectal exam	Multiparametric MRI is recommended ( → STEP 2)
Normal PSA, low suspicion	Monitoring – periodic PSA control

🔬 STEP 2 – MRI result (PI-RADS score)

PI-RADS score	What does this mean	What is done?
1–2 (negative)	Low suspicion of cancer	PSA monitoring every 6–12 months; biopsy may be avoided
1–2 , but PSA is constantly increasing	Concern despite normal MRI	Biopsy is still recommended
3 (uncertain / “gray area”)	Inconclusive result	Additional factors are evaluated (see table below)
4–5 (high suspicion)	High probability of cancer	Image-guided biopsy (MRI/ultrasound fusion + systematic biopsy)

Detail for PI-RADS 3 – additional factors

Result of the additional assessment	What is done?
Increased risk (biomarkers, PSA density)	Biopsy is recommended
Low risk	Biopsy may be postponed – monitoring

🧪 STEP 3 – Biopsy result

Biopsy result	Risk group	Treatment options
Confirmed cancer – Grade 1 (low risk)	Low risk	Active surveillance (no immediate treatment)
Confirmed cancer – Grade 2–3 (intermediate risk)	Intermediate risk	Surgery (prostatectomy) or radiotherapy or active surveillance (selected cases)
Confirmed cancer – Grade 4–5 (high risk)	High/very high risk	Radiotherapy + hormonal treatment (12–36 months) and/or surgery ± hormonal treatment
Intraductal carcinoma (non-invasive)	—	Definitive treatment or repeat MRI-guided biopsy
Atypia/atypical proliferation	—	Repeat biopsy (MRI + systematic biopsy)
Benign / High-grade PIN	—	PSA control + digital rectal exam every 12–24 months; possibly biomarkers

⚠️ Important safety rule

Situation	What needs to be done?
PSA is constantly and significantly increasing , even if the previous MRI or biopsy was negative	Repeat biopsy – a previous negative result does not completely rule out cancer

💡 Note to the patient

A low PI-RADS score or a negative biopsy does not completely rule out cancer (MRI is about 86–98% accurate). All decisions are made together with your doctor , taking into account your age, life expectancy, family history, and PSA value.

6. How Oncoexpertai helps you understand and validate your data

Correct interpretation of a PI-RADS report involves correlating numerous variables: MRI score, PSA value and dynamics, PSA density, biopsy results, and updated international guidelines — which change frequently.

Oncoexpertai platform comes in . Unlike a simple reading of a result, our advanced Artificial Intelligence algorithms instantly analyze your medical record (MRI report with PI-RADS score, PSA values and histopathology results) and correlate it with thousands of clinical studies and the latest international oncology guidelines (such as NCCN and ESMO).

Technology does not replace the doctor , but works as a digital “pre-Tumor Board”: it gives you a clear picture of your situation and helps you go to the official oncology committee with your homework done and the right questions prepared.

Disclaimer: The information in this article is for informational and educational purposes only and does not constitute medical advice, a diagnosis, or a treatment recommendation. Decisions regarding biopsy or oncological therapy should always be made in conjunction with your urologist or oncologist, in the context of your individual clinical situation.

Bibliography

American College of Radiology. PI-RADS: Prostate Imaging Reporting and Data System, Version 2.1. Reston, VA: American College of Radiology; 2019. Available from: https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/PI-RADS
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer Early Detection. Plymouth Meeting, PA: NCCN; latest version. Available from: https://www.nccn.org/guidelines
European Association of Urology. EAU Guidelines on Prostate Cancer. Arnhem: European Association of Urology; latest version. Available from: https://uroweb.org/guidelines/prostate-cancer
Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. New England Journal of Medicine. 2018;378(19):1767-1777. doi:10.1056/NEJMoa1801993.
Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer — PROMIS trial. Lancet. 2017;389(10071):815-822. doi:10.1016/S0140-6736(16)32401-1.
Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. European Urology. 2021;79(2):243-262. doi:10.1016/j.eururo.2020.09.042.
Moore CM, Kasivisvanathan V, Eggener S, Emberton M, Fütterer JJ, Gill IS, et al. Standards of reporting for MRI-targeted biopsy studies — START recommendations. European Urology. 2013;64(4):544-552. doi:10.1016/j.eururo.2013.03.030.

Dr. Onisim Florin Senior Medical Oncologist | Founder of OncoExpertAI